Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp133 | Obesity | ECE2019

Effect of IL1-receptor antagonist on renin-angiotensin-aldosterone system and hemodynamics in obese individuals

Urwyler Sandrine , Ebrahimi Fahim , Burkard Thilo , Schuetz Philipp , Poglitsch Marko , Beat Mueller , Donath Marc Y , Christ-Crain Mirjam

Background: Interleukin (IL)-1 antagonism decreases systolic blood pressure in obese individuals. However, the underlying mechanism is unknown. Based on experimental data in animals we hypothesised a blood-pressure lowering effect of IL-1-antagonism via modulation of the renin-angiotensin-aldosterone system (RAAS).Methods: In this post-hoc explorative study, we examined short- (2 days) and long-term effects (4 weeks) of IL-1 antagonism (anakinra/Kineret<...

ea0063gp137 | Obesity | ECE2019

Empagliflozin as well as Anakinra reduce symptomatic hypoglycemia in patients after Roux-Y-gastric bypass by lowered insulin secretion

Hepprich Matthias , Wiedemann Sophia , Schelker Benjamin , Starkle Alessandra , Trinh Beckey , Boni-Schnetzler Marianne , Rudofsky Gottfried , Donath Marc

Background: Postprandial hypoglycemia is an increasingly recognized complication after bariatric surgery. Its hallmark is a pronounced glycemic rise after carbohydrate ingestion followed by an exaggerated hyperinsulinemic response. Recent studies have shown that IL-1β contributes to postprandial stimulation of insulin. Furthermore, inhibition of SGLT2 reduces excessive plasma glucose increase. Therefore, we investigated whether inhibition of IL-1β with the IL-1 recep...

ea0049oc5.5 | Cardiovascular Endocrinology | ECE2017

Sex dimorphism of renal corticosteroid signaling during development and long term consequence on blood pressure

Dumeige Laurence , Storey Caroline , Decourtye Lyvianne , Nehlich Melanie , Lhadj Christophe , Viengchareun Say , Kappeler Laurent , Lombes Marc , Martinerie Laetitia

Sex differences have been demonstrated in various biological processes such as arterial blood pressure. However, the potential sex dimorphism of the renin-angiotensin-aldosterone system and, by extension, the mineralocorticoid receptor (MR) signaling pathway, major regulators of blood pressure, has only been poorly studied, notably in the kidney. Basal systolic blood pressure (SBP) and heart rate (HR) were measured in adult male and female mice. Renal gene expression studies o...

ea0049oc10.4 | Bone &amp; Calcium Homeostasis | ECE2017

The effect of denosumab or bisphosphonates in women with severe postmenopausal osteoporosis after completion of teriparatide treatment

Kocjan Tomaz , Rajic Antonela Sabati , Sever Mojca Jensterle , Vidmar Gaj , Ostanek Barbara , Marc Janja , Orehek Nina , Pfeifer Marija

The ideal antiresorptive agent to preserve or further increase bone mineral density (BMD) following teriparatide treatment is not known. We aimed to compare BMD changes after one year of therapy with denosumab or bisphosphonates in osteoporotic patients who had completed treatment with teriparatide. We retrospectively analyzed 140 women (age 74 years, 26 years from menopause, BMI 27 kg/m2 on average) with severe postmenopausal osteoporosis who had been treated betwe...

ea0049gp39 | Bone & Calcium Homeostasis 1 | ECE2017

Association of changes in serum urate level and bone mineral density during treatment with teriparatide: a retrospective observational study

Kocjan Tomaz , Vidmar Gaj , Rajic Antonela Sabati , Jensterle Sever Mojca , Pfeifer Marija , Marc Janja , Orehek Nina , Ostanek Barbara

Serum urate level has recently been associated with increased bone mineral density (BMD). Teriparatide, an osteoanabolic medication for osteoporosis, is associated with increased incidence of hyperuricemia. Hence, we hypothesized that changes in serum urate are associated with changes in BMD and procollagen type 1 N-terminal propeptide (P1NP) during treatment with teriparatide.We collected data from 151 women (mean age 72 years, mean BMI 26.6 kg/m2<...

ea0049ep1191 | Steroid metabolism + action | ECE2017

Non-alcoholic fatty liver disease and its relation with sex steroids in men

Van de Velde Frederique , Van Nieuwenhove Yves , Bekaert Marlies , Hoorens Anne , Praet Marleen , Kaufman Jean-Marc , Lapauw Bruno

Background: Obesity associates with co-morbidities as non-alcoholic fatty liver disease (NAFLD). Obese men often present with low testosterone (T) levels. As sex steroids undergo hepatic metabolization and their serum levels depend on hepatic sex hormone binding globulin (SHBG) secretion, NAFLD could contribute to this phenomenon. Previous studies however were contradictory and not based on state-of-the-art technology as mass spectrometry or biopsy-proven NAFLD.<p class="a...

ea0044p13 | Adrenal and Steroids | SFEBES2016

Characterization of clinical, biochemical and adrenal hormonal effects of ATR-101, a selective ACAT1 antagonist, in dogs with naturally-occurring Cushing’s syndrome

Hunt Stephen , Fritz Michele , Schall William , Bari Olivier N. , Smedley Rebecca , Pearson Paul , Bailey Marc , Langlois Daniel

Cushing’s syndrome (CS) in humans shares many similarities with its counterpart in dogs in terms of etiology (pituitary versus adrenal causes), clinical signs, and pathophysiologic sequelae. ATR-101 is a novel small molecule therapeutic currently in clinical development for the treatment of congenital adrenal hyperplasia and adrenocortical carcinoma in humans. ATR-101 is an adrenal-selective inhibitor of ACAT1 (acyl coenzyme A:cholesterol acyltransferase 1). ACAT1 catalyz...

ea0037ep706 | Pituitary: basic and neuroendocrinology | ECE2015

Physiological area of normality of copeptin in normal-to-hyperosmolar states

Schnyder Ingeborg , Strausz Konrad , Koch Gilbert , Walti Carla , Pfister Marc , Allolio Bruno , Fenske Wiebke Kristin , Christ-Crain Mirjam

Background: Copeptin is the C-terminal portion of the precursor of vasopressin. In contrast to vasopressin copeptin is stable in vitro and easy to measure. Similar kinetics of both peptides have been described in different trials. However, the physiological area of normality of copeptin has never been evaluated.Methods: We measured plasma copeptin, sodium, and osmolality levels in 93 healthy volunteers at baseline, during/after i.v. infusion of ...

ea0035p775 | Obesity | ECE2014

Free vs total testosterone as a marker of Leydig cell function and androgen exposure in obese male adolescents

Vandewalle Sara , Taes Youri , Fiers Tom , Maria Van Helvoirt , Patrick Debode , Jean De Schepper , Kaufman Jean-Marc

Background: Data concerning pubertal development and testosterone (T) in obese male adolescents (ObA) are scarce and contrasting. Underperforming T immunoassays and poor assessment of pubertal development might explain discordant findings. Although SHBG is markedly affected, few studies report free T (FT) levels.Objective: To study if ObA have conserved FT levels despite low total T (TT) and to investigate if FT is a better indicator of androgen exposure...

ea0070aep336 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Studying the care and social pathway of young adults with endocrine and metabolic diseases during transition: The ‘Transend’ cohort

Le Roux Enora , Menesguen Florence , Tejedor Isabelle , Halbron Marine , Popelier Marc , Faucher Pauline , Poitou Christine , Polak Michel , Touraine Philippe

Context: The transition period between pediatric and adult medicine is associated with poor patient outcomes and an important number of patients lost to follow up. Intervention exist but the few published randomized trials do not allow to study long-term patient outcomes nor intervention sustainability in time. Objective. Describe the cohort of patients in adult care who benefit from a new transition program based on case management approach, its activity and follow-up outcome...